Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

Medical team performs first hybrid procedure in the Free State
2014-12-08

The days when a heart operation meant hours in an operating theatre, with weeks and even months of convalescing, will soon be something of the past.

A team of cardiologists from the University of the Free State’s (UFS) Faculty of Health Sciences once again made medical history when they performed the first hybrid procedure in the Free State.

The Department of Paediatric Cardiology, in conjunction with the Department of Cardiothoracic Surgery, performed this very successful procedure on a 45-year-old woman from Kuruman.

During the procedure of 30 minutes, the patient’s thorax was opened up through a mini thoracotomy to operate on the beating heart.

“The patient received an artificial valve in 2011. Due to infection, a giant aneurism developed from the left ventricle, next to the aorta. Surgery would pose a very high risk to the patient. Furthermore, her health was such that it would contribute to problems during open-heart surgery,” explains Prof Stephen Brown, Head of the UFS’s Department of Paediatric Cardiology.

“After the heart was opened up through a mini thoracotomy, the paediatric cardiologists performed a direct puncture with a needle to the left ventricle cavity. A Special sheath was then placed in the left ventricle to bypass the catheters. Aided by highly advanced three-dimensional echocardiography and dihedral X-ray guidance, the opening to the aneurism, located directly below the artificial aorta valve, was identified and the aneurism cannulated.”
 
During the operation, a special coil, called a Nester Retractor, was used for the first time on a patient in South Africa to obtain stasis of extravasation and ensure the stability of devices in the aneurism.

“This is highly advanced and specialist work, as we had to make sure that the aneurism doesn’t rupture during manipulation and the devices had to be positioned in such a way that it doesn’t cause obstruction in valve function or the coronary artery. The surgical team was ready all the time to switch the patient to the heart-lung machine should something go wrong, but the procedure was very successful and the patient was discharged after a few days.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept